Ramy El Khoury, MD
Neurology · Covington, LANPI 1124380647
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,702 of the $6,617 with a category attached, or 86.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,267 and has fallen 74.1% since, to $588 in 2025.
Across 250 payments — averaging $26.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$939
- AbbVie$863
- Abbott$800
- SK Life Science, Inc.$540
- AstraZeneca$328
- Neurelis, Inc.$280
- plus $3K from 28 others
Across 3 payments — averaging $3716.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$11K
What the payments were for
- Consulting fees$80012%
- Food & beverage$5,70286%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 52 | $939 |
| AbbVie(2 entities) | 63 | $863 |
| Abbott | 1 | $800 |
| SK Life Science, Inc. | 8 | $540 |
| AstraZeneca(2 entities) | 4 | $328 |
| Neurelis, Inc. | 9 | $280 |
| Boston Scientific | 7 | $267 |
| Sanofi | 9 | $266 |
| Teva Pharmaceuticals USA, Inc. | 24 | $262 |
| Penumbra, Inc. | 2 | $188 |
| Novartis | 9 | $185 |
| Biogen | 9 | $181 |
| Pfizer | 10 | $167 |
| GE HealthCare | 5 | $156 |
| Acadia Pharmaceuticals Inc | 4 | $153 |
| GRT US Holding, Inc. | 1 | $123 |
| Eisai Inc. | 1 | $121 |
| Dexcom, Inc. | 1 | $100 |
| UCB, Inc. | 4 | $90 |
| Aquestive Therapeutics, Inc. | 3 | $89 |
| Medtronic | 1 | $84 |
| Lilly USA, LLC | 5 | $76 |
| Akcea Therapeutics, Inc. | 2 | $47 |
| Genentech USA, Inc. | 3 | $40 |
| Silk Road Medical, Inc. | 2 | $35 |
| Tersera Therapeutics LLC | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Biotronik NRO, Inc. | 1 | $33 |
| CSL Behring | 1 | $33 |
| Catalyst Pharmaceuticals, Inc. | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$800
- XCOPRI$233
- REAL System$173
- VERCISE$125
- DISEASE STATE$125
- Qutenza$123
- Cenobamate$121
- Leqembi$121
- BRILINTA$111
- NUPLAZID$107
How this compares
$6,617 in reported general payments places this provider in the 60th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 45 | $60,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $863 | $60,40245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 225 neurology providers in Louisiana.
Other neurology in Covington
- Maria Carmen WilsonCovington$295K
- Meghan HarrisShreveport$553K
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
- John EnglandNew Orleans$268K
- Ariel Antezana AntezanaAlexandria$253K
- Brian CopelandNew Orleans$211K
- Bridget BagertNew Orleans$198K
- Carol RedillasChalmette$192K
- Erik BurtonShreveport$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.